Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on April 29, 2021, at 8:00 a.m. ET to disclose its Q1 2021 financial results and share business highlights.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on April 29, 2021, at 8:00 a.m. ET to disclose its Q1 2021 financial results and share business highlights. The call can be accessed by calling 1-877-377-7098 for domestic or 1-631-291-4547 for international participants, using conference ID 4497151. The event will be available for replay on the company’s website after the live broadcast. Agios is focused on developing therapies for genetically defined diseases, with its leading candidate, mitapivat, targeting hemolytic anemias.
Positive
- Agios is advancing its clinical pipeline with mitapivat, targeting three hemolytic anemias.
- The upcoming conference call indicates transparency and engagement with investors.
Negative
- None.
Details
News Market Reaction – AGIO
The recorded move for AGIO in the trading session of this news was +3.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, April 29, 2021 at 8:00 a.m. ET to report its first quarter 2021 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 4497151. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. The company’s most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to its active late-stage clinical pipeline, Agios has multiple novel, investigational therapies in clinical and preclinical development. For more information, please visit the company’s website at www.agios.com.
Contact
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.